Journal of Immunology Research / 2015 / Article / Fig 1

Clinical Study

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Figure 1

Survival analysis. The survival analysis was performed with the Kaplan-Meier method, and a comparison of the survival curves was performed with the log-rank test. (a) The median survival time (MST) from the first vaccination of PPV was 184 days in 42 patients. (b) The patients with a JIS score of 3 (MST, 189 days) did not show significantly different survival, compared to those with a JIS score of 4 or 5 (MST, 164 days) (). (c) Combination therapy with sorafenib did not affect OS (). (d) Patients with decreased TM (tumor markers), AFP, or DCP, after vaccination (MST, 286 days) showed longer survival than those without it (MST, 180 days) ().

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.